Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $7.96 billion. The enterprise value is $7.06 billion.
| Market Cap | 7.96B |
| Enterprise Value | 7.06B |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 205.31 million shares outstanding. The number of shares has increased by 20.35% in one year.
| Current Share Class | 205.31M |
| Shares Outstanding | 205.31M |
| Shares Change (YoY) | +20.35% |
| Shares Change (QoQ) | +12.23% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 48.34% |
| Float | 78.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.28 |
| P/TBV Ratio | 9.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.09 |
| Quick Ratio | 8.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.82% and return on invested capital (ROIC) is -42.69%.
| Return on Equity (ROE) | -64.82% |
| Return on Assets (ROA) | -38.43% |
| Return on Invested Capital (ROIC) | -42.69% |
| Return on Capital Employed (ROCE) | -62.50% |
| Weighted Average Cost of Capital (WACC) | 8.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 315 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $215,000 in taxes.
| Income Tax | 215,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +140.19% in the last 52 weeks. The beta is 0.76, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +140.19% |
| 50-Day Moving Average | 31.99 |
| 200-Day Moving Average | 25.71 |
| Relative Strength Index (RSI) | 69.90 |
| Average Volume (20 Days) | 1,654,032 |
Short Selling Information
The latest short interest is 19.34 million, so 9.42% of the outstanding shares have been sold short.
| Short Interest | 19.34M |
| Short Previous Month | 19.21M |
| Short % of Shares Out | 9.42% |
| Short % of Float | 24.56% |
| Short Ratio (days to cover) | 7.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -532.90M |
| Pretax Income | -505.39M |
| Net Income | -505.61M |
| EBITDA | -532.49M |
| EBIT | -532.90M |
| Earnings Per Share (EPS) | -$2.77 |
Balance Sheet
The company has $902.11 million in cash and $72,000 in debt, with a net cash position of $902.04 million or $4.39 per share.
| Cash & Cash Equivalents | 902.11M |
| Total Debt | 72,000 |
| Net Cash | 902.04M |
| Net Cash Per Share | $4.39 |
| Equity (Book Value) | 852.59M |
| Book Value Per Share | 4.18 |
| Working Capital | 844.40M |
Cash Flow
In the last 12 months, operating cash flow was -$407.31 million and capital expenditures -$8,000, giving a free cash flow of -$407.32 million.
| Operating Cash Flow | -407.31M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 409,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -407.32M |
| FCF Per Share | -$1.98 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.35% |
| Shareholder Yield | -20.35% |
| Earnings Yield | -6.35% |
| FCF Yield | -5.11% |
Analyst Forecast
The average price target for Immunovant is $46.00, which is 18.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.00 |
| Price Target Difference | 18.59% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |